This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Winners and Losers: AstraZeneca

Health care stocks started the week mixed amid a smattering of earnings, trial data and other news.

AstraZeneca (AZN) said Monday that its heart drug Brilinta worked better than Bristol-Myers Squibb's (BMY) and Sanofi-Aventis' (SNY) blockbuster blood-thinner Plavix in a study.

According to U.K.-based AstraZeneca, the drug was more effective at preventing serious cardiac events such as myocardial infarction, stroke and cardiovascular death than clopidogrel, or Plavix, in a stage III trial. The company said it plans to submit the drug to regulatory authorities in the fourth quarter of 2009.

AstraZeneca shares were up 5.6% to $38.15. Bristol shares were down 0.5% to $20.29, and Sanofi-Aventis slipped 1% to $29.86.

Meanwhile, The Wall Street Journal is reporting that the deaths of two patients in Delaware who took Baxter's (BAX) blood-thinner heparin have spurred concern of a contamination akin to one in 2008. A third patient also had medical problems, according to The Journal.

A representative for Baxter told the paper that the drug involved in the deaths contained bulk material supplied by Pfizer (PFE). Pfizer couldn't be reached for comment by The Journal. In the approximately 80 deaths that were linked to tainted heparin last year, the bulk material came from China, Baxter said.

"We are not pointing fingers at Baxter," Wallace Hudson of Beebe Medical Center, which confirmed the deaths, told The Journal. "We don't know what's going on, but heparin is the only commonality that we were able to see ourselves." The heparin is being tested, but so far no problems have been found, the report said.

Baxter shares were up 0.2% to $50.36. Pfizer shares were down 1.7% to $14.15.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,138.87 +107.73 0.63%
S&P 500 2,000.67 +16.54 0.83%
NASDAQ 4,557.7350 +38.8330 0.86%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs